Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV

Biochemistry

Volumn 53, Issue 34, 2014, Pages 5558-5567

  Aldred, Katie J ^a   Breland, Erin J ^a   Vlčková, Vladislava ^a   Strub, Marie Paule ^c   Neuman, Keir C ^c   Kerns, Robert J ^b   Osheroff, Neil ^a,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INTERACTIONS; ENZYMES; METAL IONS;

BACILLUS ANTHRACIS; CIPROFLOXACIN; CLINICAL USE; DNA CLEAVAGE; DRUG ACTIVITIES; DRUG BINDING; RELAXATION RATES; TOPOISOMERASE IV;

ESCHERICHIA COLI;

CIPROFLOXACIN; DNA; DNA TOPOISOMERASE IV; METAL; WATER;

BIOCATALYSIS; CHEMISTRY; ENZYMOLOGY; ESCHERICHIA COLI; METABOLISM;

BIOCATALYSIS; CIPROFLOXACIN; DNA; DNA TOPOISOMERASE IV; ESCHERICHIA COLI; METALS; WATER;

EID: 84906877854     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi500682e     Document Type: Article

References (59)

1. Hooper, D. C. (1999) Mode of action of fluoroquinolones Drugs 58 (Suppl. 2) 6-10
2. Anderson, V. E. and Osheroff, N. (2001) Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde Curr. Pharm. Des. 7, 337-353
3. Hooper, D. C. (2001) Mechanisms of action of antimicrobials: Focus on fluoroquinolones Clin. Infect. Dis. 32 (Suppl. 1) S9-S15
4. Drlica, K., Malik, M., Kerns, R. J., and Zhao, X. (2008) Quinolone-mediated bacterial death Antimicrob. Agents Chemother. 52, 385-392
5. Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., and Zhao, X. (2009) Quinolones: Action and resistance updated Curr. Top. Med. Chem. 9, 981-998
6. Aldred, K. J., Kerns, R. J., and Osheroff, N. (2014) Mechanism of quinolone action and resistance Biochemistry 53, 1565-1574
7. Levine, C., Hiasa, H., and Marians, K. J. (1998) DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities Biochim. Biophys. Acta 1400, 29-43
8. Champoux, J. J. (2001) DNA topoisomerases: Structure, function, and mechanism Annu. Rev. Biochem. 70, 369-413
9. Gentry, A. C. and Osheroff, N. (2013) DNA topoisomerases: Type II. In Encyclopedia of Biological Chemistry, pp 163-168, Elsevier Inc., Amsterdam.
10. Aubry, A., Fisher, L. M., Jarlier, V., and Cambau, E. (2006) First functional characterization of a singly expressed bacterial type II topoisomerase: The enzyme from Mycobacterium tuberculosis Biochem. Biophys. Res. Commun. 348, 158-165
11. Schoeffler, A. J. and Berger, J. M. (2008) DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology Q. Rev. Biophys. 41, 41-101
12. Deweese, J. E., Osheroff, M. A., and Osheroff, N. (2009) DNA topology and topoisomerases: Teaching a "knotty" subject Biochem. Mol. Biol. Educ. 37, 2-10
13. Liu, Z., Deibler, R. W., Chan, H. S., and Zechiedrich, L. (2009) The why and how of DNA unlinking Nucleic Acids Res. 37, 661-671
14. Tretter, E. M., Lerman, J. C., and Berger, J. M. (2010) A naturally chimeric type IIA topoisomerase in Aquifex aeolicus highlights an evolutionary path for the emergence of functional paralogs Proc. Natl. Acad. Sci. U.S.A. 107, 22055-22059
15. Deweese, J. E. and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing Nucleic Acids Res. 37, 738-749
16. Khodursky, A. B., Zechiedrich, E. L., and Cozzarelli, N. R. (1995) Topoisomerase IV is a target of quinolones in Escherichia coli Proc. Natl. Acad. Sci. U.S.A. 92, 11801-11805
17. Fournier, B., Zhao, X., Lu, T., Drlica, K., and Hooper, D. C. (2000) Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone-induced inhibition of DNA synthesis Antimicrob. Agents Chemother. 44, 2160-2165
18. Munoz, R. and De la Campa, A. G. (1996) ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype Antimicrob. Agents Chemother. 40, 2252-2257
19. Pan, X.-S., Ambler, J., Mehtar, S., and Fisher, L. M. (1996) Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae Antimicrob. Agents Chemother. 40, 2321-2326
20. Pan, X.-S. and Fisher, L. M. (1997) Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones Antimicrob. Agents Chemother. 41, 471-474
21. Pan, X.-S. and Fisher, L. M. (1998) DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae Antimicrob. Agents Chemother. 42, 2810-2816
22. Higgins, C. F., Dorman, C. J., Stirling, D. A., Waddell, L., Booth, I. R., May, G., and Bremer, E. (1988) A physiological role for DNA supercoiling in the osmotic regulation of gene expression in S. typhimurium and E. coli Cell 52, 569-584
23. Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X. S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases Nat. Struct. Mol. Biol. 16, 667-669
24. Laponogov, I., Pan, X. S., Veselkov, D. A., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2010) Structural basis of gate-DNA breakage and resealing by type II topoisomerases PLoS One 5, e11338
25. Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K. K., Lewis, C. J., May, E. W., Saunders, M. R., Singh, O., Spitzfaden, C. E., Shen, C., Shillings, A., Theobald, A. J., Wohlkonig, A., Pearson, N. D., and Gwynn, M. N. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466, 935-940
26. Wohlkonig, A., Chan, P. F., Fosberry, A. P., Homes, P., Huang, J., Kranz, M., Leydon, V. R., Miles, T. J., Pearson, N. D., Perera, R. L., Shillings, A. J., Gwynn, M. N., and Bax, B. D. (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance Nat. Struct. Mol. Biol. 17, 1152-1153
27. Aldred, K. J., McPherson, S. A., Wang, P., Kerns, R. J., Graves, D. E., Turnbough, C. L., Jr., and Osheroff, N. (2012) Drug interactions with Bacillus anthracis topoisomerase IV: Biochemical basis for quinolone action and resistance Biochemistry 51, 370-381
28. Aldred, K. J., McPherson, S. A., Turnbough, C. L., Jr., Kerns, R. J., and Osheroff, N. (2013) Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance Nucleic Acids Res. 41, 4628-4639
29. Aldred, K. J., Schwanz, H. A., Li, G., McPherson, S. A., Turnbough, C. L., Jr., Kerns, R. J., and Osheroff, N. (2013) Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions ACS Chem. Biol. 8, 2660-2668
30. Dalhoff, A. (2012) Resistance surveillance studies: A multifaceted problem-the fluoroquinolone example Infection 40, 239-262
31. Yoshida, H., Kojima, T., Yamagishi, J., and Nakamura, S. (1988) Quinolone-resistant mutations of the gyrA gene of Escherichia coli Mol. Gen. Genet. 211, 1-7
32. Cullen, M. E., Wyke, A. W., Kuroda, R., and Fisher, L. M. (1989) Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones Antimicrob. Agents Chemother. 33, 886-894
33. Drlica, K. and Zhao, X. (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones Microbiol. Mol. Biol. Rev. 61, 377-392
34. Li, Z., Deguchi, T., Yasuda, M., Kawamura, T., Kanematsu, E., Nishino, Y., Ishihara, S., and Kawada, Y. (1998) Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis Antimicrob. Agents Chemother. 42, 3293-3295
35. Price, L. B., Vogler, A., Pearson, T., Busch, J. D., Schupp, J. M., and Keim, P. (2003) In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin Antimicrob. Agents Chemother. 47, 2362-2365
36. Bast, D. J., Athamna, A., Duncan, C. L., de Azavedo, J. C., Low, D. E., Rahav, G., Farrell, D., and Rubinstein, E. (2004) Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance J. Antimicrob. Chemother. 54, 90-94
37. Grohs, P., Podglajen, I., and Gutmann, L. (2004) Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations Antimicrob. Agents Chemother. 48, 3024-3027
38. Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., and Zechiedrich, L. (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates Antimicrob. Agents Chemother. 53, 235-241
39. Yang, J., Luo, Y., Li, J., Ma, Y., Hu, C., Jin, S., Ye, L., and Cui, S. (2010) Characterization of clinical Escherichia coli isolates from China containing transferable quinolone resistance determinants J. Antimicrob. Chemother. 65, 453-459
40. Lautenbach, E., Metlay, J. P., Mao, X., Han, X., Fishman, N. O., Bilker, W. B., Tolomeo, P., Wheeler, M., and Nachamkin, I. (2010) The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients Clin. Infect. Dis. 51, 280-285
41. Bansal, S. and Tandon, V. (2011) Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates Int. J. Antimicrob. Agents 37, 253-255
42. Hardin, A. H., Sarkar, S. K., Seol, Y., Liou, G. F., Osheroff, N., and Neuman, K. C. (2011) Direct measurement of DNA bending by type IIA topoisomerases: Implications for non-equilibrium topology simplification Nucleic Acids Res. 39, 5729-5743
43. Corbett, K. D., Schoeffler, A. J., Thomsen, N. D., and Berger, J. M. (2005) The structural basis for substrate specificity in DNA topoisomerase IV J. Mol. Biol. 351, 545-561
44. Fortune, J. M., Velea, L., Graves, D. E., Utsugi, T., Yamada, Y., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition Biochemistry 38, 15580-15586
45. Malik, M., Marks, K. R., Mustaev, A., Zhao, X., Chavda, K., Kerns, R. J., and Drlica, K. (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis Antimicrob. Agents Chemother. 55, 2335-2343
46. Fortune, J. M. and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage J. Biol. Chem. 273, 17643-17650
47. Fortune, J. M. and Osheroff, N. (2001) Topoisomerase II-catalyzed relaxation and catenation of plasmid DNA Methods Mol. Biol. 95, 275-281
48. Robinson, M. J. and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II Biochemistry 30, 1807-1813
49. Gentry, A. C., Pitts, S. L., Jablonsky, M. J., Bailly, C., Graves, D. E., and Osheroff, N. (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: Implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage Biochemistry 50, 3240-3249
50. Hiasa, H. (2002) The Glu-84 of the ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions Biochemistry 41, 11779-11785
51. Pfeiffer, E. S. and Hiasa, H. (2007) Determination of the primary target of a quinolone drug and the effect of quinolone resistance-conferring mutations by measuring quinolone sensitivity based on its mode of action Antimicrob. Agents Chemother. 51, 3410-3412
52. Tran, T. P., Ellsworth, E. L., Sanchez, J. P., Watson, B. M., Stier, M. A., Showalter, H. D., Domagala, J. M., Shapiro, M. A., Joannides, E. T., Gracheck, S. J., Nguyen, D. Q., Bird, P., Yip, J., Sharadendu, A., Ha, C., Ramezani, S., Wu, X., and Singh, R. (2007) Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors Bioorg. Med. Chem. Lett. 17, 1312-1320
53. German, N., Malik, M., Rosen, J. D., Drlica, K., and Kerns, R. J. (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2, 4-diones Antimicrob. Agents Chemother. 52, 3915-3921
54. Pan, X. S., Gould, K. A., and Fisher, L. M. (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV Antimicrob. Agents Chemother. 53, 3822-3831
55. Oppegard, L. M., Streck, K. R., Rosen, J. D., Schwanz, H. A., Drlica, K., Kerns, R. J., and Hiasa, H. (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones Antimicrob. Agents Chemother. 54, 3011-3014
56. Anderson, V. E., Zaniewski, R. P., Kaczmarek, F. S., Gootz, T. D., and Osheroff, N. (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV: Changes in drug mechanism across evolutionary boundaries J. Biol. Chem. 274, 35927-35932
57. Anderson, V. E., Zaniewski, R. P., Kaczmarek, F. S., Gootz, T. D., and Osheroff, N. (2000) Action of quinolones against Staphylococcus aureus topoisomerase IV: Basis for DNA cleavage enhancement Biochemistry 39, 2726-2732
58. Anderson, V. E., Gootz, T. D., and Osheroff, N. (1998) Topoisomerase IV catalysis and the mechanism of quinolone action J. Biol. Chem. 273, 17879-17885
59. Emmerson, A. M. and Jones, A. M. (2003) The quinolones: Decades of development and use J. Antimicrob. Chemother. 51 (Suppl. 1) 13-20